Genzyme to Acquire Diagnostic Chemicals Division

Robert Buderi11/8/07

Cambridge-based Genzyme announced on Wednesday that it has agreed to acquire the diagnostic division of Canada’s Diagnostic Chemicals. Terms of the all-cash agreement were undisclosed. The acquisition, involving DCL operations in Prince Edward Island and Connecticut, brings into the Genzyme fold some 50 formulated clinical chemistry reagents, which garnered roughly $21 million in revenues in DCL’s 2007 fiscal year, according to a statement

Bob is Xconomy's founder and editor in chief. You can e-mail him at bbuderi@xconomy.com, call him at 617.500.5926, or follow him on Twitter at http://twitter.com/bbuderi.